Clinical Trial Update: A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating QLS32015 as monotherapy versus Pomalidomide plus Dexamethasone or Selinexor plus Dexamethasone in relapsed or refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalyst (pomalidomide)
• QLS32015 (QLS32015)
• Selinexor (selinexor)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: RECRUITING